Published in J Pathol on March 01, 2009
Antigen retrieval immunohistochemistry: review and future prospects in research and diagnosis over two decades. J Histochem Cytochem (2011) 2.70
Factors influencing the degradation of archival formalin-fixed paraffin-embedded tissue sections. J Histochem Cytochem (2011) 1.49
Protein extraction of formalin-fixed, paraffin-embedded tissue enables robust proteomic profiles by mass spectrometry. J Histochem Cytochem (2009) 1.30
Toward deciphering proteomes of formalin-fixed paraffin-embedded (FFPE) tissues. Proteomics (2012) 1.23
Miswiring the brain: Δ9-tetrahydrocannabinol disrupts cortical development by inducing an SCG10/stathmin-2 degradation pathway. EMBO J (2014) 1.11
Successful protein extraction from over-fixed and long-term stored formalin-fixed tissues. PLoS One (2011) 1.08
Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations. J Proteome Res (2010) 1.07
Complete solubilization of formalin-fixed, paraffin-embedded tissue may improve proteomic studies. Proteomics Clin Appl (2013) 0.95
Targeted therapies in cancer - challenges and chances offered by newly developed techniques for protein analysis in clinical tissues. J Cancer (2010) 0.86
Liquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discovery. J Proteome Res (2009) 0.85
Improved protein extraction and protein identification from archival formalin-fixed paraffin-embedded human aortas. Proteomics Clin Appl (2013) 0.84
Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays. Mol Cell Proteomics (2013) 0.84
Validation of a robust proteomic analysis carried out on formalin-fixed paraffin-embedded tissues of the pancreas obtained from mouse and human. Proteomics (2012) 0.83
Neocortical synaptophysin asymmetry and behavioral lateralization in chimpanzees (Pan troglodytes). Eur J Neurosci (2010) 0.81
Dietary L-arginine supplementation affects the skeletal longissimus muscle proteome in finishing pigs. PLoS One (2015) 0.80
Extraction of tamoxifen and its metabolites from formalin-fixed, paraffin-embedded tissues: an innovative quantitation method using liquid chromatography and tandem mass spectrometry. Cancer Chemother Pharmacol (2014) 0.79
Novel in situ pretreatment method for significantly enhancing the signal in MALDI-TOF MS of formalin-fixed paraffin-embedded tissue sections. PLoS One (2012) 0.79
Immunohistochemical analysis of retinoblastoma and β-catenin as an assistant tool in the differential diagnosis between Crohn's disease and ulcerative colitis. PLoS One (2013) 0.77
Evaluation of formalin-fixed paraffin-embedded tissues in the proteomic analysis of parathyroid glands. Proteome Sci (2011) 0.77
Reverse Phase Protein Arrays-Quantitative Assessment of Multiple Biomarkers in Biopsies for Clinical Use. Microarrays (Basel) (2015) 0.76
Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA). Mol Cell Proteomics (2015) 0.76
Increased frequency of anti-retina antibodies in asymptomatic patients with chronic t. gondii infection. Clinics (Sao Paulo) (2010) 0.76
Elucidating drivers of oral epithelial dysplasia formation and malignant transformation to cancer using RNAseq. Oncotarget (2015) 0.75
The expression of Lamin A mutant R321X leads to endoplasmic reticulum stress with aberrant Ca(2+) handling. J Cell Mol Med (2016) 0.75
A novel xylene-free deparaffinization method for the extraction of proteins from human derived formalin-fixed paraffin embedded (FFPE) archival tissue blocks. MethodsX (2014) 0.75
[Analysis of signalling pathways in formalin-fixed breast cancer tissues]. Pathologe (2010) 0.75
[Update on protein analysis of fixed tissues]. Pathologe (2010) 0.75
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med (2003) 8.93
Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial. J Clin Oncol (2004) 5.84
Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res (2009) 3.70
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res (2006) 2.87
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res (2013) 2.45
Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology (2007) 2.45
Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. Proteomics (2004) 2.43
Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics (2003) 2.17
Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics (2005) 1.69
DNA double strand break repair in human bladder cancer is error prone and involves microhomology-associated end-joining. Nucleic Acids Res (2004) 1.67
Serum aminoacylase-1 is a novel biomarker with potential prognostic utility for long-term outcome in patients with delayed graft function following renal transplantation. Kidney Int (2013) 1.61
Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma. Clin Cancer Res (2009) 1.49
Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem (2005) 1.46
MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res (2010) 1.44
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Factor analysis of the Hospital Anxiety and Depression Scale from a large cancer population. Psychol Psychother (2002) 1.40
A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet (2011) 1.34
Sonic hedgehog regulates prostatic growth and epithelial differentiation. Dev Biol (2003) 1.32
Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci (2004) 1.29
Banking of biological fluids for studies of disease-associated protein biomarkers. Mol Cell Proteomics (2008) 1.27
Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma. Cancer Res (2005) 1.27
Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: identification of key issues affecting potential clinical utility. Cancer Res (2003) 1.26
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res (2007) 1.25
Mutation analysis of the 8p candidate tumour suppressor genes DBC2 (RHOBTB2) and LZTS1 in bladder cancer. Cancer Lett (2004) 1.23
A Rasch and factor analysis of the Functional Assessment of Cancer Therapy-General (FACT-G). Health Qual Life Outcomes (2007) 1.19
The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology (2008) 1.18
Mining the archival formalin-fixed paraffin-embedded tissue proteome: opportunities and challenges. Mol Biosyst (2008) 1.18
CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. Br J Haematol (2008) 1.17
Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol (2003) 1.16
Autocrine regulation of human urothelial cell proliferation and migration during regenerative responses in vitro. Exp Cell Res (2005) 1.13
Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer (2006) 1.12
Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization. Clin Cancer Res (2011) 1.12
Psychosocial care for cancer patients in primary care? Recognition of opportunities for cancer care. Fam Pract (2004) 1.11
Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol (2002) 1.10
Proteomic analysis of primary cell lines identifies protein changes present in renal cell carcinoma. Proteomics (2006) 1.10
Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial. Eur J Cancer (2010) 1.09
Impact of patient-reported outcomes in oncology: a longitudinal analysis of patient-physician communication. J Clin Oncol (2011) 1.09
Proteomic analysis of formalin-fixed paraffin-embedded renal tissue samples by label-free MS: assessment of overall technical variability and the impact of block age. Proteomics Clin Appl (2013) 1.08
Renal cancer biomarkers: the promise of personalized care. BMC Med (2012) 1.08
Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations. J Proteome Res (2010) 1.07
Integrated multi-level quality control for proteomic profiling studies using mass spectrometry. BMC Bioinformatics (2008) 1.04
Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clin Appl (2010) 1.04
APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res (2005) 1.03
A systematic analysis of the effects of increasing degrees of serum immunodepletion in terms of depth of coverage and other key aspects in top-down and bottom-up proteomic analyses. Proteomics (2011) 1.02
Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene (2005) 1.01
Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy? Clin Cancer Res (2011) 1.00
Closely related mycobacterial strains demonstrate contrasting levels of efficacy as antitumor vaccines and are processed for major histocompatibility complex class I presentation by multiple routes in dendritic cells. Infect Immun (2005) 0.99
Comprehensive analysis of CDKN2A status in microdissected urothelial cell carcinoma reveals potential haploinsufficiency, a high frequency of homozygous co-deletion and associations with clinical phenotype. Clin Cancer Res (2005) 0.98
Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. Int J Cancer (2005) 0.96
Prognostic factors in renal cell carcinoma: association of preoperative sodium concentration with survival. Clin Cancer Res (2008) 0.96
Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One (2012) 0.95
Proteomic analysis of increased Parkin expression and its interactants provides evidence for a role in modulation of mitochondrial function. Proteomics (2009) 0.94
The JAK/STAT pathway is not sufficient to sustain the antiproliferative response in an interferon-resistant human melanoma cell line. Melanoma Res (2003) 0.92
Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma. Proteomics (2006) 0.92
Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr Relat Cancer (2014) 0.92
Sample size determination in clinical proteomic profiling experiments using mass spectrometry for class comparison. Proteomics (2009) 0.91
Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol (2002) 0.90
Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int (2013) 0.90
Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Proteomics (2009) 0.89